Hot Spotlight

Breakthrough in Parkinson's Treatment: Positive Phase 3 Trial Results for Cerevel's Tavapadon

28 April 2024
2 min read

On April 18th, Cerevel announced the positive top-line results from its pivotal Phase 3 TEMPO-3 trial for tavapadon, the company's first and only D1/D5 receptor partial agonist, intended for the treatment of Parkinson's disease.

The TEMPO-3 trial assessed the efficacy, safety, and tolerability of tavapadon as a once-daily adjunctive therapy to levodopa in adult patients with Parkinson's disease. The trial demonstrated that, over a period of 27 weeks, patients treated with tavapadon experienced a statistically significant increase in total "ON time" without troublesome dyskinesia compared to those receiving placebo. Specifically, the clinical significance and statistical increase in "ON time" without troublesome dyskinesia was marked by an additional 1.1 hours (1.7 hours versus 0.6 hours, p<0.0001). The tavapadon treatment group also observed a statistically significant reduction in "OFF time," a key secondary endpoint.

These findings indicate that tavapadon may offer an appropriate balance of motor control, safety, and tolerability for patients with Parkinson's disease. Further results from the Phase 3 TEMPO-1 and TEMPO-2 trials of tavapadon as monotherapy are expected to be released in the second half of 2024.

Tavapadon (formerly known as PF-6649751) is a selective D1 and D5 receptor agonist originally developed by Pfizer. It is currently being developed by Cerevel for the clinical treatment of psychomotor disorders and Parkinson's disease.

图示

描述已自动生成

About Cerevel

Cerevel Therapeutics was established at the end of 2018 in collaboration with Pfizer and Bain Capital. It is a clinical-stage biopharmaceutical company that combines a profound understanding of brain biology and neural circuitry with advanced chemistry and pharmacology of central nervous system receptors to discover and develop new therapies.

In December 2023, AbbVie announced plans to acquire Cerevel Therapeutics through a transformative transaction to enhance its pipeline strength in the field of neuroscience. This proposed acquisition is expected to bring a rich pipeline of top potential assets focused on unmet needs in psychiatry and neuroscience to AbbVie. It will complement AbbVie's current market portfolio and its emerging neuroscience pipeline, with the total transaction equity value estimated at approximately $8.7 billion.

图形用户界面, 文本, 应用程序

描述已自动生成

Alkermes has started the Vibrance-1 Phase 2 trial to assess ALKS 2680 for treating Narcolepsy Type 1
Latest Hotspot
3 min read
Alkermes has started the Vibrance-1 Phase 2 trial to assess ALKS 2680 for treating Narcolepsy Type 1
28 April 2024
Alkermes plc has launched the Vibrance-1 study, a phase 2 clinical trial aimed at assessing the safety and effectiveness of ALKS 2680 versus a placebo in individuals diagnosed with type 1 narcolepsy.
Read →
What is Triple-Negative Breast Cancer?
"What" Series
2 min read
What is Triple-Negative Breast Cancer?
28 April 2024
Triple-Negative Breast Cancer (TNBC) is a subtype of breast cancer that lacks estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER-2) on its cells.
Read →
Atom Bioscience begins enrolling U.S. participants in a worldwide Phase 2b/3 study of an experimental chronic gout therapy
Latest Hotspot
2 min read
Atom Bioscience begins enrolling U.S. participants in a worldwide Phase 2b/3 study of an experimental chronic gout therapy
28 April 2024
Atom Bioscience focused on innovative therapies for metabolic and inflammatory conditions, has initiated patient enrollment across the United States for a Phase 2b/3 study of ABP-671.
Read →
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - April 27
Pharma Frontiers
10 min read
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - April 27
28 April 2024
April 27th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.